[CLAIMS]

1. An α,β-unsaturated amide compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof:



(I)

wherein,

"A" represents optionally substituted heterocyclic diyl,

R^1 represents hydrogen atom or optionally substituted lower alkyl,

R^2 represents optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aliphatic heterocyclic group or optionally substituted aromatic heterocyclic group,

X represents -O-, -S-, -SO_2-, -NR^{X1}- (wherein, R^{X1} represents hydrogen atom or lower alkyl), -CHR^{X2}- (wherein, R^{X2} represents hydrogen atom or hydroxy), -CH=CH-, -CO- or -NH-CO-,

n1 and n2 are the same or different, and each represents 0 or 1, and

the heterocyclic diyl in the optionally substituted heterocyclic diyl is heterocyclic diyl selected from the group consisting of benzoxazolediyl, benzothiazolediyl, 2,3-dihydrobenzothiophenediyl, 3,4-dihydropyranopyridinediyl, 2,3,4,5-tetrahydrobenzoxazepinediyl, 2,3,4,5-tetrahydrobenzoxepinediyl and 2,3-dihydrobenzofurandiyl.

2. The α,β-unsaturated amide compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein R^1 is hydrogen atom.

3. The α,β-unsaturated amide compound or a pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein R^2 is optionally substituted aryl or optionally substituted aromatic heterocyclic group.

4. A pharmaceutical composition comprising the α,β-unsaturated amide compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3 and a carrier.

5. A prophylactic or therapeutic agent for cancer comprising the α,β-unsaturated amide compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3 as an active ingredient.

6. The prophylactic or therapeutic agent according to claim 5, wherein the cancer is one or two or more selected from the group consisting of mesothelioma, lung cancer, ovarian cancer, and liver cancer.

7. The α,β-unsaturated amide compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3 for use as a medicine.

8. Use of the α,β-unsaturated amide compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, in the manufacture of a prophylactic or therapeutic agent for cancer.

9. The use according to claim 8, wherein the cancer is one or two or more selected from the group consisting of mesothelioma, lung cancer, ovarian cancer, and liver cancer.